Carregant...
Immunotherapeutic approaches for small-cell lung cancer
Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the first-line setting, the addition of the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab to...
Guardat en:
| Publicat a: | Nat Rev Clin Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212527/ https://ncbi.nlm.nih.gov/pubmed/32055013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41571-019-0316-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|